Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 12, 2026, titled "Zydus expands companion diagnostics portfolio with the launch of AI-powered Continuous Glucose Monitor DiasensTM and GlucoLiveTM".
Press Release Mar 12 2026
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced the launch of AI-powered Continuous Glucose Monitors, DiasensTM and GlucoLiveTM, expanding its companion diagnostics portfolio. These devices are designed for patients with diabetes, Chronic Kidney Disease, and those who have undergone transplants, providing continuous glycaemic monitoring and integrated remote care. The launch aims to enhance patient convenience and improve quality of life by offering real-time glucose data and analytics through a dedicated mobile application.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Feb 28 2026
- Press Release Feb 27 2026
- Press Release Feb 25 2026
- Press Release Feb 19 2026
- Press Release Feb 18 2026
Later from Zydus Lifesciences
- Press Release Mar 13 2026
- Press Release Mar 14 2026
- Press Release Mar 16 2026
- Press Release Mar 17 2026
- Press Release Mar 18 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences